Clinical Trials at NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
As of September 2026, 53 paid clinical trials are recruiting at NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, located at 622 W 168TH ST, NEW YORK, NY 10032-3720, phone (212) 305-5974 in New York, New York. Active studies at this site cover conditions such as Breast Cancer, Prostate Cancer and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
53 clinical trials at NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
·Clear filters·Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Project: Every Child for Younger Patients With Cancer
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Common conditions studied in New York
- Breast Cancer (91 active studies)
- Prostate Cancer (75 active studies)
- Ovarian Cancer (43 active studies)
- Colorectal Cancer (42 active studies)
- Multiple Myeloma (42 active studies)
- Heart Failure (38 active studies)
Leading research sponsors in New York
- Memorial Sloan Kettering Cancer Center
- NYU Langone Health
- Columbia University
- Icahn School of Medicine at Mount Sinai
- Weill Medical College of Cornell University
Frequently asked questions
How many paid clinical trials are currently recruiting in New York?
There are approximately 3,395 recruiting clinical trials in New York, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New York pay participants?
Most recruiting trials in New York compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New York?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New York?
The most common conditions under active study in New York include Breast Cancer (91), Prostate Cancer (75), Ovarian Cancer (43), Colorectal Cancer (42), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New York?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New York on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New York?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New York?
Recruiting research sites in New York include Memorial Sloan Kettering Cancer Center, NYU Langone Health, Icahn School of Medicine at Mount Sinai, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New York right now?
The largest active categories in New York are Cancer & tumors (1,129), Cardiovascular (203), Neurology & pain (202). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center?
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center is located at 622 W 168TH ST, NEW YORK, NY 10032-3720. Use the Google Maps link in the intro above to get directions.
How do I contact NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center?
You can reach NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center by phone at (212) 305-5974. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.